Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NYSE | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 8, 22 | -0.93
Decreased by
-520.00%
|
-1.01
Increased by
+7.92%
|
Mar 2, 22 | -0.75
Decreased by
-120.59%
|
-0.25
Decreased by
-200.00%
|
Nov 3, 21 | -0.35
Increased by
+70.59%
|
-0.44
Increased by
+20.45%
|
Jul 28, 21 | -0.34 | -0.37
Increased by
+8.11%
|
Nov 4, 20 | -0.15 | -0.15 |
Jul 29, 20 | -0.34 | -0.15
Decreased by
-126.67%
|
Jun 30, 20 | -1.19 | -0.54
Decreased by
-122.22%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-7.62 M
Decreased by
-167.59%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-8.72 M
Decreased by
-245.33%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-5.89 M
Decreased by
-84.21%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-5.91 M
Decreased by
-246.98%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-2.85 M
Decreased by
-183.02%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
-2.52 M
Decreased by
-9.31%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 0.00
Decreased by
N/A%
|
-3.20 M
Decreased by
-624.58%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
N/A%
|
-1.70 M
Decreased by
-746.99%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.